Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

ut microbiota-derived metabolites are novel targets for improving insulin resistanc

Full text
Author(s):
Bastos, Rosana M. C. [1] ; Rangel, Erika B. [2, 1]
Total Authors: 2
Affiliation:
[1] Hosp Israelita Albert Einstein, Albert Einstein 627, Bldg A, 2SS, BR-05652001 Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Div Nephrol, BR-04023900 Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: WORLD JOURNAL OF DIABETES; v. 13, n. 1, p. 65-69, JAN 15 2022.
Web of Science Citations: 0
Abstract

The gut microbiota plays a key role in metabolic diseases. Gut-microbiota-derived metabolites are found in different dietary sources, including: Carbohydrate (acetate, propionate, butyrate, also known as short-chain fatty acids, as well as succinate); protein (hydrogen sulfide, indole, and phenylacetic acid); and lipids (resveratrol-, ferulic acid-, linoleic acid-, catechin- and berry-derived metabolites). Insulin resistance, which is a global pandemic metabolic disease that progresses to type 2 diabetes mellitus, can be directly targeted by these metabolites. Gut-microbiota-derived metabolites have broad effects locally and in distinct organs, in particular skeletal muscle, adipose tissue, and liver. These metabolites can modulate glucose metabolism, including the increase in glucose uptake and lipid oxidation in skeletal muscle, and decrease in lipogenesis and gluconeogenesis associated with lipid oxidation in the liver through activation of phosphatidylinositol 3-kinase - serine/threonine-protein kinase B and AMP-activated protein kinase. In adipose tissue, gut-microbiota-derived metabolites stimulate adipogenesis and thermogenesis, inhibit lipolysis, and attenuate inflammation. Importantly, an increase in energy expenditure and fat oxidation occurs in the whole body. Therefore, the therapeutic potential of current pharmacological and non-pharmacological approaches used to treat diabetes mellitus can be tested to target specific metabolites derived from intestinal bacteria, which may ultimately ameliorate the hyperglycemic burden. (AU)

FAPESP's process: 17/23195-2 - Mesenchymal stem cell therapy for halting the progression of acute and chronic kidney injury and in vivo modulate kidney-derived c-Kit stem cells
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants
FAPESP's process: 13/19560-6 - C-kit positive cells are kidney-specific stem cells that have regenerative capacity
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants